[1] |
Weiss LM, Dubey JP.Toxoplasmosis: a history of clinical observations[J]. Int J Parasitol, 2009, 39(8): 895-901.
|
[2] |
吴斌, 吕芳丽. CD8+T 细胞免疫应答在刚地弓形虫感染免疫中的功能研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(2): 143-147.
|
[3] |
Fox BA, Bzik DJ.De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii[J]. Nature, 2002, 415(6874): 926-929.
|
[4] |
Fox BA, Bzik DJ.Avirulent uracil auxotrophs based on disruption of orotidine-5′-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii[J]. Infect Immun, 2010, 78(9): 3744-3752.
|
[5] |
Fox BA, Bzik DJ, Kiah LS.Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression[J]. Onco-immunology, 2013, 2(11): e26296.
|
[6] |
Gigley JP, Fox BA, Bzik DJ.Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication[J]. J Immunol, 2009, 182(2): 1069-1078.
|
[7] |
Behnke MS, Fentress SJ, Mashayekhi M, et al. The polymorphic pseudokinase ROP5 controls virulence in Toxoplasma gondii by regulating the active kinase ROP18[J]. PLoS Pathog, 2012, 8(11): e1002992.
|
[8] |
Butcher BA, Fox BA, Rommereim LM, et al. Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control[J]. PLoS Pathog, 2011, 7(9): e1002236.
|
[9] |
Rosowski EE, Lu D, Julien L, et al. Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein[J]. J Exp Med, 2011, 208(1): 195-212.
|
[10] |
Braun L, Brenier-Pinchart MP, Yogavel M, et al. A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation[J]. J Exp Med, 2013, 210(10): 2071-2086.
|
[11] |
Peixoto L, Chen F, Harb OS, et al. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses[J]. Cell Host Microbe, 2010, 8(2): 208-218.
|
[12] |
Fox BA, Sanders KL, Rommereim LM, et al. Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of antitumor immunity[J]. PLoS Genet, 2016, 12(7): e1006189.
|
[13] |
Ravindran S, Lodoen MB, Verhelst SH, et al. 4-Bromophenacyl bromide specifically inhibits rhoptry secretion during Toxoplasma invasion[J]. PLoS One, 2009, 4(12): e8143.
|
[14] |
Denkers EY, Butcher BA, Del RL, et al. Neutrophils, dendritic cells and Toxoplasma[J]. Int J Parasitol, 2004, 34(3): 411-421.
|
[15] |
Johnson LL, VanderVegt FP, Havell EA. Gamma interferon-dependent temporary resistance to acute Toxoplasma gondii infection independent of CD4+ or CD8+ lymphocytes[J]. Infect Immun, 1993, 61(12): 5174-5180.
|
[16] |
Hunter CA, Subauste CS, Van Cleave VH, et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha[J]. Infect Immun, 1994, 62(7): 2818-2824.
|
[17] |
Hemmi H, Akira S.TLR signalling and the function of dendritic cells[J]. Chem Immunol Allergy, 2005, 86: 120-135.
|
[18] |
Bagchi A, Herrup EA, Warren HS, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists[J]. J Immunol, 2007, 178(2): 1164-1171.
|
[19] |
曾治民, 何静, 刘安文. Toll样受体信号传导与炎症相关肿瘤的关系[J]. 中国癌症杂志, 2011, 21(6): 489-494.
|
[20] |
Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody[J]. J Clin Oncol, 2007, 25(7): 876-883.
|
[21] |
Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily[J]. Mol Cell Biol, 2000, 20(15): 5503-5515.
|
[22] |
Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A[J]. Nat Med, 2004, 10(9): 950-958.
|
[23] |
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat med, 2004, 10(9): 942-949.
|
[24] |
Trinchieri G.Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity[J]. Annu Rev Immunol, 1995, 13: 251-276.
|
[25] |
Mashayekhi M, Sandau MM, Dunay IR, et al. CD8α(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites[J]. Immunity, 2011, 35(2): 249-259.
|
[26] |
Airoldi I, Di Carlo E, Cocco C, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells[J]. Proc Natl Acad Sci USA, 2007, 104(10): 3996-4001.
|
[27] |
Murugaiyan G, Saha B.Protumor vs antitumor functions of IL-17[J]. J Immunol, 2009, 183(7): 4169-4175.
|
[28] |
Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2008, 58(2): 71-96.
|
[29] |
Schreiber RD, Old LJ, Smyth MJ.Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
|
[30] |
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity[J]. Cancer Res, 2008, 68(18): 7684-7691.
|
[31] |
Baird JR, Fox BA, Sanders KL, et al. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment[J]. Cancer Res, 2013, 73(13): 3842-3851.
|
[32] |
Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppres-sive to immunostimulatory cells[J]. Cancer Res, 2009, 69(18): 7329-7337.
|
[33] |
Palucka K, Banchereau J.Cancer immunotherapy via dendritic cells[J]. Nat Rev Cancer, 2012, 12(4): 265-277.
|
[34] |
Benson A, Murray S, Divakar P, et al. Microbial infection induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism[J]. J Immunol, 2012, 188(2): 800-810.
|
[35] |
Komita H, Zhao X, Katakam AK, et al. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity[J]. Cancer gene ther, 2009, 16(12): 883-891.
|
[36] |
Wilson DC, Matthews S, Yap GS.IL-12 signaling drives CD8+ T cell IFN-gamma production and differentiation of KLRG1+ effector subpopulations during Toxoplasma gondii infection[J]. J Immunol, 2008, 180(9): 5935-5945.
|
[37] |
Zou W, Restifo NP.T(H)17 cells in tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2010, 10(4): 248-256. [38] Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks[J]. Nat Rev Immunol, 2013, 13(7): 499-509.
|
[39] |
Gazzinelli RT, Wysocka M, Hayashi S, et al. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii[J]. J Immunol, 1994, 153(6): 2533-2543.
|
[40] |
Bougdour A, Durandau E, Brenier-Pinchart MP, et al. Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression[J]. Cell Host Microbe, 2013, 13(4): 489-500.
|
[41] |
吕文超, 崔云甫. 胰腺癌流行病学和病因学研究进展[J]. 世界华人消化杂志, 2011, 19(27): 2805-2809.
|
[42] |
Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer[J]. Cancer Cell, 2012, 21(6): 822-835.
|
[43] |
Sideras K, Braat H, Kwekkeboom J, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies[J]. Cancer Treat Rev, 2014, 40(4): 513-522.
|
[44] |
Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer[J]. Immunotherapy, 2013, 5(10): 1075-1087.
|
[45] |
Sanders KL, Fox BA, et al. Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations[J]. Cancer Immunol Res, 2015, 3(8): 891-901.
|
[46] |
Pützer BM, Rödicker F, Hitt MM, et al. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model[J]. Mol Ther, 2002, 5(4): 405-412.
|
[47] |
Zaidi MR, Merlino G.The two faces of interferon-γ in cancer[J]. Clin Cancer Res, 2011, 17(19): 6118-6124.
|
[48] |
Sanders KL, Fox BA, Bzik DJ.Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer[J]. Oncoimmunology, 2016, 5(4): e1104447.
|
[49] |
Wang J, Saffold S, Cao X, et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines[J]. J Immunol, 1998, 161(10): 5516-5524.
|
[50] |
Baird JR, Byrne KT, Lizotte PH, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge[J]. J Immunol, 2013, 190(1): 469-478.
|